Age, risk and outcomes in idiopathic pulmonary arterial hypertension
- PMID: 29724788
- DOI: 10.1183/13993003.00629-2018
Age, risk and outcomes in idiopathic pulmonary arterial hypertension
Conflict of interest statement
Conflict of interest: M.M. Hoeper has received fees for lectures and/or consultations from Actelion, Bayer, Gilead, GSK, MSD and Pfizer. Conflict of interest: A. Boucly has received fees for lectures from Actelion, and non-financial support from Actelion, Bayer, GSK and Merck. Conflict of interest: O. Sitbon has received grants and/or personal fees and/or non-financial support from Actelion, Bayer, GSK, Merck and Arena Pharmaceuticals.
Comment on
-
Impact of age and comorbidity on risk stratification in idiopathic pulmonary arterial hypertension.Eur Respir J. 2018 May 3;51(5):1702310. doi: 10.1183/13993003.02310-2017. Print 2018 May. Eur Respir J. 2018. PMID: 29622568
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical